ArticleMolecules (Basel, Switzerland)2022
The Synthesis and Initial Evaluation of MerTK Targeted PET Agents.
Li Wang, Yubai Zhou, Xuedan Wu, Xinrui Ma, Bing Li, Ransheng Ding, Michael A Stashko, Zhanhong Wu, Xiaodong Wang, Zibo Li
Open access · goldAbstract read
In one paragraphArticle in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors at 1 institution in 1 country.
Li WangBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.ORCID 0000-0003-0284-5958 Yubai ZhouCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-3704-283X Xuedan WuBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Xinrui MaBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.ORCID 0000-0002-7970-3387 Bing LiCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Ransheng DingCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Michael A StashkoCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Zhanhong WuBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Xiaodong WangCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Zibo LiBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.ORCID 0000-0002-1063-0298 University of North Carolina at Chapel Hill · US
Funding
Novel Catalytic Methods for Efficient Radiolabeling of Un-activated Arene Compounds SupplementR01EB029451 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO, NICEWICZ, DAVID A · 2020 to 2023
$2.2MDevelopment of IDO PET agents for immunotherapyR01CA233904 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO, MOSCHOS, STERGIOS · 2019 to 2023
$2.0MSmall Animal PET/CT for Preclinical Imaging ResearchS10OD023611 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO · 2017 to 2017
$835kNIH HHS 1S10OD023611NIH HHS 5R01CA233904NIH HHS 5R01EB029451
6 · The paper itselfAbstract
MerTK (Mer tyrosine kinase), a receptor tyrosine kinase, is ectopically or aberrantly expressed in numerous human hematologic and solid malignancies. Although a variety of MerTK targeting therapies are being developed to enhance outcomes for patients with various cancers, the sensitivity of tumors to MerTK suppression may not be uniform due to the heterogeneity of solid tumors and different tumor stages. In this report, we develop a series of radiolabeled agents as potential MerTK PET (positron emission tomography) agents. In our initial in vivo evaluation, [
Indexed as
c-Mer Tyrosine KinasePositron-Emission TomographyRadiopharmaceuticalsAnimalsCell Line, TumorFluorine RadioisotopesHumansMiceTissue Distributionc-Mer Tyrosine KinaseFluorine RadioisotopesMERTK protein, humanRadiopharmaceuticalscancerfluorine-18MerTKpositron emission tomographyradiolabeling
Identifiers
PMID35268561
PMCPMC8911752
OpenAlexW4220965349
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390